Insulin mimetics and non-canonical insulin receptor signaling: mechanisms and disease relevance
- 1Department of Oral Histology and Developmental Biology, School of Dentistry, Seoul National University
- 2Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University
Abstract
Insulin receptor (IR) signaling has traditionally been viewed as a canonical pathway in which insulin binding uniformly activates downstream metabolic and mitogenic responses. However, growing evidence indicates that IR signaling is not monolithic. Instead, IR signaling is increasingly recognized as a context-dependent process in which receptor conformation, spatial organization, and intracellular trafficking shape signaling outcomes. These non-canonical regulatory mechanisms generate distinct signaling states that can differentially regulate metabolic, mitogenic, immune, and neuronal functions. Recent advances in engineered insulin mimetics, including peptides, antibodies, aptamers, and de novo designed ligands, have provided powerful tools to probe this signaling diversity. By stabilizing specific receptor conformations or engagement geometries, these ligands can selectively bias downstream signaling programs. Here we discuss recent insights into how the qualitative features of IR signaling, rather than signaling amplitude alone, determine disease outcomes across diverse pathological contexts. Understanding this signaling diversity may enable the rational design of next-generation insulin mimetics and more precise therapeutic strategies targeting IR pathways.
Related
- Spatial encryption of G protein-coupled receptor signaling in endosomes; Mechanisms and applications
- Wnt/β-catenin and D2 receptor signaling crosstalk in disease mechanisms
- Exercise mimetics: molecular mechanisms, biological and therapeutic effects
- Regulatory mechanisms of programmed cell death in hyperuricaemia and their disease relevance
- Fzd7 (Frizzled-7) Expressed by Endothelial Cells Controls Blood Vessel Formation Through Wnt/β-Catenin Canonical Signaling
BibTeX
@article{park2026insulin,
title = {{Insulin mimetics and non-canonical insulin receptor signaling: mechanisms and disease relevance}},
author = {Junhee Park and Eunhee Choi},
journal = {Experimental and Molecular Medicine},
year = {2026},
month = oct,
doi = {10.1038/s12276-026-01862-5},
url = {https://doi.org/10.1038/s12276-026-01862-5},
note = {CC BY},
}
RIS
TY - JOUR
TI - Insulin mimetics and non-canonical insulin receptor signaling: mechanisms and disease relevance
AU - Junhee Park
AU - Eunhee Choi
PY - 2026
DA - 2026/10/01
JO - Experimental and Molecular Medicine
DO - 10.1038/s12276-026-01862-5
UR - https://doi.org/10.1038/s12276-026-01862-5
AB - Insulin receptor (IR) signaling has traditionally been viewed as a canonical pathway in which insulin binding uniformly activates downstream metabolic and mitogenic responses. However, growing evidence indicates that IR signaling is not monolithic. Instead, IR signaling is increasingly recognized as a context-dependent process in which receptor conformation, spatial organization, and intracellular trafficking shape signaling outcomes. These non-canonical regulatory mechanisms generate distinct signaling states that can differentially regulate metabolic, mitogenic, immune, and neuronal functions. Recent advances in engineered insulin mimetics, including peptides, antibodies, aptamers, and de novo designed ligands, have provided powerful tools to probe this signaling diversity. By stabilizing specific receptor conformations or engagement geometries, these ligands can selectively bias downstream signaling programs. Here we discuss recent insights into how the qualitative features of IR signaling, rather than signaling amplitude alone, determine disease outcomes across diverse pathological contexts. Understanding this signaling diversity may enable the rational design of next-generation insulin mimetics and more precise therapeutic strategies targeting IR pathways.
SN - 2092-6413
SN - 1226-3613
ER -